Q2 Commentary
• Reported trading profit $212 million, up 17% underlying
• EPSA increased 10% to 15.4 cents
• Orthopaedics continues to be impacted by deferred procedures
• Endoscopy achieved strong repair product sales off-set by the weak capital related market
• Advanced Wound Management delivered another good sales and profit performance
• Trading margin improved 310 basis points to 22.9%
• Interim dividend increased by 10% to 5.46¢
